Dr JACQUINOT Quentin

Fiche personne

coordonnées

Institut régional fédératif du cancer de Franche-Comté
CHU de Besançon
2 Bd Fleming

25030 BESANCON Cedex

03 70 63 20 58

qjacquinot@irfc-fc.fr

Territoire

Franche-Comté

affiliation

Centre hospitalier régional universitaire de Besançon (CHRU Besançon)

Recherche

Mots clés : Activité physique adaptée APA

Publications

Exercise Intervention on Insomnia in Patients with a Cancer: A Systematic Review of the Literature.

Drozd C, Curtit E, Gillet V, Jacquinot Q, Meneveau N, Mougin F

Cancers (Basel). 2024 06 17;16(12):

A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study.

Drozd C, Curtit E, Jacquinot Q, Marquine C, Mansi L, Chaigneau L, Dobi E, Viot J, Meynard G, Paillard MJ, Goujon M, Roux P, Vernerey D, Gillet V, Bourdin H, Galli S, Meneveau N, Mougin F

BMC Cancer. 2023 05 17;23(1):449

[Physical activity in the oncology care pathway: Expectations and perspectives].

Foucaut AM, Jacquinot Q, Ginsbourger T, Turnaco L, Lamotte R, Mougin F,

Bull Cancer. 2023 05 9;:

There is a need for a complete consideration of overall movement behaviors for the prevention, treatment, and follow-up of cancer risks and patients.

Ennequin G, Delrieu L, Rossary A, Jacquinot Q, Mougin F, Thivel D, Duclos M

Front Public Health. 2022 12 19;10:1080941

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.

Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, Roux P, Degano B, Chatot M, Curtit E, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Meynard G, Vernerey D, Pivot X, Mougin F

Front Cardiovasc Med. 2022 09 23;9:1000846

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma.

d'Engremont C, Grillot J, Raillat J, Vernerey D, Vuitton L, Koch S, Turco C, Heyd B, Mouillet G, Jacquinot Q, Borg C, Vienot A

Front Oncol. 2021 ;11:683289

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

Jacquinot Q, Paget-Bailly S, Fumoleau P, Romieu G, Pierga JY, Espié M, Lortholary A, Nabholtz JM, Mercier CF, Pauporté I, Henriques J, Pivot X

Breast. 2018 Jun 15;41:1-7

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.

Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M, Dumoulin G, Vernerey D, Pivot X, Mougin F

BMC Cancer. 2017 Jun 19;17(1):425